Nektar Therapeutics
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company, discovers, develops and commercializes therapies that selectively modulate the immune system to treat autoimmune disorders, inflammatory conditions and cancer; its lead product candidate, rezpegaldesleukin (REZPEG), is a regulatory T cell stimulator in Phase 2b clinical development for atopic dermatitis, alopecia areata and new-onset Type 1 diabetes, with FDA Fast Track designation granted for severe-to-very-severe alopecia areata in 2025; the company's immuno-oncology pipeline features NKTR-255, an engineered IL-15 receptor agonist evaluated in ongoing trials in combination with checkpoint inhibitors, TIL therapy and CAR-T therapies for solid tumors and hematological malignancies; preclinical programs include NKTR-0165, a TNFR2 agonist antibody for multiple sclerosis, vitiligo and ulcerative colitis with a planned first-in-human study in 2026, NKTR-0166, a TNFR2 bispecific antibody for rheumatic diseases, and NKTR-422, a CSF1R agonist for inflammation resolution. Founded in 1990 and headquartered in San Francisco, California, Nektar Therapeutics operates primarily in the United States with global clinical trial activities and partnerships extending internationally; the company leverages proprietary polymer conjugate technologies and immunology expertise to enhance drug pharmacokinetics, efficacy and patient convenience across autoimmune, inflammatory and oncology segments, targeting patients with unmet needs in immune-mediated diseases. Recent developments include completion of enrollment in the REZOLVE-AA Phase 2b trial for rezpegaldesleukin in alopecia areata and REZOLVE-AD trial data presentations at EADV and ACAAI 2025 meetings demonstrating statistical significance in endpoints for atopic dermatitis; in early 2025, Nektar initiated a Phase 2 trial agreement with TrialNet for rezpegaldesleukin in Type 1 diabetes and advanced IND-enabling studies for NKTR-0165 and NKTR-0166; the company completed a $115 million public offering and ATM proceeds to bolster its balance sheet, while selling royalties on CIMZIA and MIRCERA to Royalty Pharma in a non-dilutive transaction, and Ampersand Capital Partners acquired its PEGylation reagent manufacturing business in late 2024.
Company News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Nektar Therapeutics Q2 Earnings Call Highlights
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm
Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Thursday
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Up – What’s Next?
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)